Decitabine Induces Ferroptosis in Myelodysplastic Syndrome

Decitabine in myelodysplastic syndromes

Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome

PURPOSE The DNA methylation inhibitor 5-aza-2'-deoxycytidine (DAC) is approved for the treatment of myelodysplastic syndromes (MDS), but resistance to DAC develops during treatment and mechanisms of resistance remain unknown. Therefore, we investigated mechanisms of primary and secondary resistance to DAC in MDS. PATIENTS AND METHODS We performed Quantitative Real-Time PCR to examine expressi...

Decitabine dosage in myelodysplastic syndromes

contained a chromosome 7 abnormality (also mostly monosomy 7). Four of 11 patients with complex karyotype including aberrations of chromosome 7 showed cytogenetic responses (Figure 1; Table 1) compared with 2 responders of 9 patients with complex karyotype not containing a chromosome 7 abnormality. This high response rate in patients with chromosome 7 abnormalities is in stark contrast to the n...

Ionizing radiation induces ferroptosis in splenic lymphocytes of mice

Backgrounds: It remains unclear whether radiation-induced haemorrhage in the spleen causes iron accumulation, and subsequently, ferroptosis in splenic lymphocytes. In this study, we investigated the occurrence of ferroptosis in splenic lymphocytes of gamma-irradiated mice. Materials and Methods: Mice were subjected to gamma radiation from a 137Cs source. Iron, Ferroportin 1, and iron regulatory...

Decitabine in the treatment of myelodysplastic syndromes

Myelodysplastic syndromes (MDS) are a group of heterogeneous clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral blood cytopenias and a propensity to transform into acute myeloid leukemia. There are few treatment options available for patients with MDS. Studies into the molecular biology of MDS have demonstrated abnormal patterns of DNA methylation th...